AR032475A1 - Un compuesto derivado de quinazolina, su uso, procedimiento para prepararlo, y una composicion farmaceutica que lo comprende - Google Patents
Un compuesto derivado de quinazolina, su uso, procedimiento para prepararlo, y una composicion farmaceutica que lo comprendeInfo
- Publication number
- AR032475A1 AR032475A1 ARP010104130A ARP010104130A AR032475A1 AR 032475 A1 AR032475 A1 AR 032475A1 AR P010104130 A ARP010104130 A AR P010104130A AR P010104130 A ARP010104130 A AR P010104130A AR 032475 A1 AR032475 A1 AR 032475A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- hydrogen
- heterocyclyl
- heteroaryl
- cyano
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- 201000001880 Sexual dysfunction Diseases 0.000 abstract 1
- 208000027520 Somatoform disease Diseases 0.000 abstract 1
- 208000026723 Urinary tract disease Diseases 0.000 abstract 1
- 125000004423 acyloxy group Chemical group 0.000 abstract 1
- 239000000674 adrenergic antagonist Substances 0.000 abstract 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 102000030619 alpha-1 Adrenergic Receptor Human genes 0.000 abstract 1
- 108020004102 alpha-1 Adrenergic Receptor Proteins 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- -1 individual isomers Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 208000027753 pain disease Diseases 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 231100000872 sexual dysfunction Toxicity 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 208000014001 urinary system disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Compuestos que son de una forma general antagonistas del receptor adrenérgico alfa-1B, y los cuales se representan por la formula general (1), en donde R1 es hidrogeno o alquilo-(C1-6); R2 es alquilo-(C1-6), heterociclilo o heteroarilo o arilo insustituidos, o heterociclilo o heteroarilo o arilo sustituido por alquilo-(C1-6), alcoxi, halogeno o ciano; R' y R'', son cada una de ellas, independientemente con respecto a la otra, alquilo-(C1-6); A es hidrogeno, -(CH2)0-1R3, -C(O)R3, -SO2R3, -C(O)OR3, -C(O)NR4R5, -SO2NR4R5, -C(NR6)R3 o -C(NR6)NR4R5; R3 es, indpendientemente en cada caso, alquilo-(C1-6) insustituido, o alquilo-(C1-6) sustituido por halogeno, amino, alquilamino, hidroxi, alcoxi, aciloxi, aminocarbonilo, alcoxicarbonilamino, nitro, o ciano; o arilo; arialquilo, heteroarilo, heteroarilalquilo, cicloalquilo, cicloalquilaquilo, heterociclilo o heterociclilalquilo; R4 y R5 son, independientemente la una con respecto a la otra, hidrogeno, o R4 y R5, tomadas conjuntamente con los carbonos a los cuales éstas se encuentran unidas, forman un anillo de 5 a 7 miembros, opcionalmente, incorporando uno o dos heteroátomos del anillo elegidos de entre N, S u O; R6 es hidrogeno, alquilo inferior o ciano; y n es un numero entero de 0 a 2,. inclusive, y m es un numero entero de 0 a 3, inclusive, en donde m+n, es igual o mayor de 2; o profármacos, isomeros individuales, mezclas de isomeros, racémicas o no racémicas, o sales o solvatos farmacéuticamente aceptables de éstos. Composiciones farmacéuticas que contiene tales tipos de componentes, uso de tales tipos de compuestos, en el control y la prevencion de enfermedades, tales como los trastornos del tracto urinario, la disfuncion sexual, el dolor, o los trastornos del sistema nervioso central, y procedimientos para la preparacion de éstos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22950300P | 2000-08-31 | 2000-08-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR032475A1 true AR032475A1 (es) | 2003-11-12 |
Family
ID=22861517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010104130A AR032475A1 (es) | 2000-08-31 | 2001-08-30 | Un compuesto derivado de quinazolina, su uso, procedimiento para prepararlo, y una composicion farmaceutica que lo comprende |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US6559153B2 (es) |
| EP (1) | EP1315714B1 (es) |
| JP (1) | JP3971299B2 (es) |
| KR (1) | KR100602929B1 (es) |
| CN (1) | CN1308324C (es) |
| AR (1) | AR032475A1 (es) |
| AT (1) | ATE309240T1 (es) |
| AU (2) | AU2001293788B2 (es) |
| BR (1) | BR0113585A (es) |
| CA (1) | CA2420177C (es) |
| DE (1) | DE60114852T2 (es) |
| ES (1) | ES2251512T3 (es) |
| GT (1) | GT200100181A (es) |
| MX (1) | MXPA03001777A (es) |
| PA (1) | PA8527901A1 (es) |
| PE (1) | PE20020407A1 (es) |
| UY (1) | UY26919A1 (es) |
| WO (1) | WO2002018348A2 (es) |
| ZA (1) | ZA200301082B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60215195T2 (de) | 2001-08-10 | 2007-08-23 | Monash University, Clayton | Derivate morphinähnlicher opioidverbindungen |
| WO2003082825A1 (en) * | 2002-04-03 | 2003-10-09 | Orion Corporation | Use of an alfa2-adrenoreceptor antagonist for cns-related diseases |
| TW200403058A (en) * | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
| ITMI20030151A1 (it) * | 2003-01-30 | 2004-07-31 | Recordati Ind Chimica E Farma Ceutica S P A | Uso di antagonisti selettivi del recettore mglu5 per il trattamento di disfunzioni neuromuscolari del tratto urinario inferiore. |
| DE602004022819D1 (de) * | 2003-06-06 | 2009-10-08 | Vertex Pharma | Von atp-bindende kassette transportern |
| NZ545506A (en) * | 2003-07-24 | 2009-11-27 | Euro Celtique Sa | Therapeutic agents useful for treating pain |
| WO2006021345A2 (en) * | 2004-08-27 | 2006-03-02 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with adrenergic alpha-1b receptor (adra1b) |
| MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
| US7413607B2 (en) * | 2005-03-31 | 2008-08-19 | 3M Innovative Properties Company | Templated semiconductor particles and methods of making |
| US7344583B2 (en) * | 2005-03-31 | 2008-03-18 | 3M Innovative Properties Company | Methods of making metal particles within cored dendrimers |
| JP4796624B2 (ja) * | 2005-05-04 | 2011-10-19 | エフ．ホフマン−ラ ロシュ アーゲー | ５−ｈｔ受容体に作用する（３，４−ジヒドロ−キナゾリン−２−イル）−（２−アリールオキシ−エチル）−アミン類 |
| WO2007125321A2 (en) | 2006-04-25 | 2007-11-08 | Astex Therapeutics Limited | Purine and deazapurine derivatives as pharmaceutical compounds |
| WO2008036700A2 (en) * | 2006-09-19 | 2008-03-27 | 3M Innovative Properties Company | Templated metal oxide particles and methods of making |
| RS53552B1 (en) | 2007-10-11 | 2015-02-27 | Astrazeneca Ab | DERIVATI PIROLO [2,3-D] PIRIMIDINA KAO INHIBITORI PROTEIN KINAZE B |
| TW200944526A (en) * | 2008-04-22 | 2009-11-01 | Vitae Pharmaceuticals Inc | Carbamate and urea inhibitors of 11β-hydroxysteroid dehydrogenase 1 |
| AU2012235902B2 (en) | 2011-04-01 | 2015-08-27 | Astrazeneca Ab | Therapeutic treatment |
| JP6309454B2 (ja) | 2011-11-30 | 2018-04-11 | アストラゼネカ アクチボラグ | 癌の併用処置 |
| AU2013204533B2 (en) | 2012-04-17 | 2017-02-02 | Astrazeneca Ab | Crystalline forms |
| BR112019018774A2 (pt) * | 2017-03-12 | 2020-04-07 | Wang Xiaodong | composto tendo uma estrutura de acordo com a fórmula i, sal farmaceuticamente aceitável, composição farmacêutica, método para prevenir ou tratar uma doença ou afeção e método para imunomodulação, inibição ou prevenção de rejeição de enxertos de órgãos ou pele ou tratamento de tumores ou câncer |
| WO2019088095A1 (ja) * | 2017-11-02 | 2019-05-09 | 国立大学法人九州大学 | 鎮痛剤及びその使用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2232138A1 (en) | 1995-09-29 | 1997-04-03 | William C. Lumma | Alpha 1b adrenergic receptor antagonists |
| NZ325248A (en) * | 1995-12-23 | 1999-09-29 | Pfizer Res & Dev | Quinoline and quinazoline compounds useful in therapy |
| GB9700504D0 (en) | 1997-01-11 | 1997-02-26 | Pfizer Ltd | Pharmaceutical compounds |
| US6355641B1 (en) | 1999-03-17 | 2002-03-12 | Syntex (U.S.A.) Llc | Oxazolone derivatives and uses thereof |
-
2001
- 2001-08-23 BR BR0113585-6A patent/BR0113585A/pt not_active IP Right Cessation
- 2001-08-23 CA CA002420177A patent/CA2420177C/en not_active Expired - Fee Related
- 2001-08-23 AT AT01974210T patent/ATE309240T1/de not_active IP Right Cessation
- 2001-08-23 AU AU2001293788A patent/AU2001293788B2/en not_active Ceased
- 2001-08-23 AU AU9378801A patent/AU9378801A/xx active Pending
- 2001-08-23 ES ES01974210T patent/ES2251512T3/es not_active Expired - Lifetime
- 2001-08-23 KR KR1020037002933A patent/KR100602929B1/ko not_active IP Right Cessation
- 2001-08-23 EP EP01974210A patent/EP1315714B1/en not_active Expired - Lifetime
- 2001-08-23 MX MXPA03001777A patent/MXPA03001777A/es active IP Right Grant
- 2001-08-23 JP JP2002523466A patent/JP3971299B2/ja not_active Expired - Fee Related
- 2001-08-23 CN CNB018165958A patent/CN1308324C/zh not_active Expired - Fee Related
- 2001-08-23 WO PCT/EP2001/009749 patent/WO2002018348A2/en active IP Right Grant
- 2001-08-23 DE DE60114852T patent/DE60114852T2/de not_active Expired - Fee Related
- 2001-08-29 US US09/942,385 patent/US6559153B2/en not_active Expired - Fee Related
- 2001-08-29 PE PE2001000870A patent/PE20020407A1/es not_active Application Discontinuation
- 2001-08-30 PA PA20018527901A patent/PA8527901A1/es unknown
- 2001-08-30 AR ARP010104130A patent/AR032475A1/es unknown
- 2001-08-30 UY UY26919A patent/UY26919A1/es not_active Application Discontinuation
- 2001-08-30 GT GT200100181A patent/GT200100181A/es unknown
-
2003
- 2003-02-07 ZA ZA200301082A patent/ZA200301082B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2251512T3 (es) | 2006-05-01 |
| PA8527901A1 (es) | 2002-07-30 |
| ZA200301082B (en) | 2004-05-07 |
| ATE309240T1 (de) | 2005-11-15 |
| DE60114852D1 (de) | 2005-12-15 |
| CA2420177C (en) | 2008-07-08 |
| CN1545510A (zh) | 2004-11-10 |
| CA2420177A1 (en) | 2002-03-07 |
| CN1308324C (zh) | 2007-04-04 |
| BR0113585A (pt) | 2003-07-29 |
| AU2001293788B2 (en) | 2007-10-11 |
| KR20030022421A (ko) | 2003-03-15 |
| JP3971299B2 (ja) | 2007-09-05 |
| GT200100181A (es) | 2002-05-23 |
| US6559153B2 (en) | 2003-05-06 |
| PE20020407A1 (es) | 2002-05-21 |
| DE60114852T2 (de) | 2006-07-27 |
| US20020045614A1 (en) | 2002-04-18 |
| WO2002018348A2 (en) | 2002-03-07 |
| UY26919A1 (es) | 2002-02-28 |
| EP1315714B1 (en) | 2005-11-09 |
| WO2002018348A3 (en) | 2002-07-11 |
| EP1315714A2 (en) | 2003-06-04 |
| KR100602929B1 (ko) | 2006-07-20 |
| MXPA03001777A (es) | 2003-06-04 |
| AU9378801A (en) | 2002-03-13 |
| JP2004507527A (ja) | 2004-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR032475A1 (es) | Un compuesto derivado de quinazolina, su uso, procedimiento para prepararlo, y una composicion farmaceutica que lo comprende | |
| AR035775A1 (es) | Compuestos derivados de quinazolin-4-ona y benzo[1,2,4]tiadiazina-1,1-dióxido, su uso, un proceso para su obtencion y composiciones farmaceuticas que los contienen | |
| AR050184A1 (es) | Inhibidores macrociclicos de beta-secretasa | |
| EA200600190A1 (ru) | Производные пиримидин-2,4-диона в качестве антагонистов рецептора гонадотропин-высвобождающего гормона | |
| EA200600811A1 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ | |
| HRP20100594T1 (hr) | Derivati 2-amino-kinazolina koji se koriste kao inhibitori b-sekretaze (bace) | |
| EA200500088A1 (ru) | Трициклические модуляторы ядерного рецептора стероидного гормона | |
| KR950701323A (ko) | 1-피페라지노-1,2-디히드로인덴 유도체(1-Piperazino-1,2-dihydroindene Derivatives) | |
| EA200200716A1 (ru) | Арилконденсированные азаполициклические соединения | |
| BRPI0514661B8 (pt) | antagonistas de vasopressina v1a, composição farmacêutica e uso dos referidos antagonistas | |
| PA8491101A1 (es) | Derivados de 4-fenil-piridin. | |
| UY27336A1 (es) | Derivados de 4-piperacinilindol con afinidad receptora de 5-ht6 | |
| ECSP034563A (es) | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti-inflamatorios y analgesicos | |
| ES2168237T1 (es) | Pirazolopirimidinas que actuan como antagonistas del receptor del crf. | |
| PE20040937A1 (es) | Derivados de piridazin-3(2h)-ona como inhibidores de fosfodiesterasa-4 (pde 4) | |
| CA2523261A1 (en) | Fused pyrimidine derivatives with crf activity | |
| EA200970928A1 (ru) | Антагонисты рецептора гонадотропин-рилизин-фактора и способы их применения | |
| BRPI0517425A (pt) | composto ou um sal, solvato, enanciÈmero, diastereÈmero ou mistura de diastereÈmeros do mesmo, composição farmacêutica, uso de composto | |
| UY27503A1 (es) | Nuevos derivados de piperazina | |
| EA200401526A1 (ru) | Новые соединения и их применение | |
| AR035502A1 (es) | Un compuesto derivado de tipo fenil-sustituido cetona como antagonistas del receptor de prostaglandina i2 (ip), una composicion farmaceutica que comprende a dicho compuesto, uso del mismo y un proceso para preparar dicho compuesto | |
| AR044662A1 (es) | Compuestos de azetidina | |
| ES2180041T3 (es) | Derivados de 5-oxido de piridazino(4,5-b)quinoleina, su preparacion y su uso como antagonistas de glicina. | |
| AR037611A1 (es) | Compuestos derivados de amino-tetralina, su uso, un procedimiento para su preparacion y composiciones farmaceuticas que los comprenden | |
| AR015446A1 (es) | Antagonistas de receptores de vitronectina, composicion farmaceutica que los contiene, procedimiento para su preparacion, su uso para la elaboracion de unmedicamento y compuestos intermediarios |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |